Astrum is an international contract research organization (CRO) providing full-service clinical development solutions to biotech companies worldwide. With a team of over 250 professionals across Europe, Astrum combines the scientific rigor of a large CRO with the agility and responsiveness that emerging biotech sponsors need to advance their programs efficiently.

Astrum operates a proprietary 64-bed Phase I clinical unit in Porto, Portugal, inspected by EMA, FDA, ANVISA & enabling early-phase studies including single and multiple ascending dose, drug-drug interaction, bioequivalence, and food effect trials in healthy volunteers and patients, including critical indications through its integrated intensive care unit.

Beyond early phase, Astrum offers strong experience in Phase II and Phase III clinical trials, with particular expertise in oncology, immunology, and central nervous system (CNS) indications. Astrum also holds CIR (Crédit Impôt Recherche) accreditation in France, allowing French sponsors to optimize their R&D investment through significant tax benefits. Astrum is headquartered in Europe, with a large operational coverage across countries and a long-standing US partnership ensuring transatlantic trial execution.